HIMS Reclaims $34 as Options Flow Front-Runs the July Peptide Decision

The Bid With No Headline

There is no discrete company announcement attached to this 24-hour pop. HIMS is up 11.37% to $34.08, and the cleanest read on the tape is positioning: TheFly flagged bullish CBOE options flow as the stock pushed roughly 11.5% higher, with call activity leading the move rather than a press release.

The fundamental cover for that flow is a week old. Barclays' Glen Santangelo raised his price target to $39 from $29 and kept an Overweight rating, citing "a clear inflection" in the GLP-1 weight-loss business following the March partnership with Novo Nordisk. That call put a number on a recovery that was already underway, and traders are now leaning on it ahead of a calendar event. Treat this honestly as momentum into a known catalyst, not a reaction to something new that hit the wire today.

Six Weeks From the May Lows

This is the same stock HIPERWIRE last covered in mid-May, when HIMS was sliding to $24.93 as JP Morgan, BofA, and Jefferies all cut targets after a Q1 miss that compressed gross margin 800 basis points. The bull case then — a telehealth distribution layer scaling through branded GLP-1 — was intact but pushed out, and the tape repriced the gap. Six weeks later the stock is roughly 37% off those lows.

What changed is the data, not the story. Barclays pointed to May website traffic running 35% higher year-over-year and monthly active app users up 21%, the first hard evidence that the Novo Nordisk distribution shift is pulling volume rather than just trading high-margin compounded revenue for low-margin branded units. Novo itself has now called Hims one of its most "voluminous" telehealth partners — a notable turn given the two sides publicly fell out over compounded GLP-1 sales a year ago. The margin trough flagged in May still has depth, but the volume base it was waiting on is showing up.

The July Vote That Actually Matters

The reason there is a bid into a quiet week is a date on the calendar. The FDA's Pharmacy Compounding Advisory Committee meets July 23-24 to decide whether seven peptides should be added to the 503A bulk substances list. A favorable vote would let compounding pharmacies — Hims among them — manufacture those peptides, opening what bulls frame as the next major product category beyond GLP-1.

The sell side is split on how much to pay for it now. Leerink called the meeting "a potentially important catalyst" while keeping a Market Perform rating and a $25 target, arguing near-term attention stays on GLP-1 profitability. The upside case is far louder: FirstWave Fund's Jonah Lupton floated $10-19 billion in annual peptide revenue by 2030 at just 4-5% market capture — an aggressive number worth treating as a ceiling, not a base case. Either way, the event is binary and known, which is exactly the kind of setup options flow front-runs.

The Setup

The $30 level that acted as resistance through April is now reclaimed as support, with $32 the nearer pivot and the $70.43 52-week high sitting far above as a reminder of how far this name traveled before the May reset. On Hyperliquid, the HIP-3 HIMS perp turned just $4.53M over the last 24 hours — a thin book that amplifies both the squeeze higher and any unwind. With the FDA vote still more than three weeks out, the obvious risk is a buy-the-rumor drift that fades if the committee disappoints or if GLP-1 margin commentary resurfaces before then. For now the stock is trading the catalyst, not the print.